文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDOPA与18F-FDG PET显像评估临床前髓外多发性骨髓瘤美法仑治疗反应

Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with 18F-FDOPA and 18F-FDG PET.
PubMed 文献 · J Nucl Med · 2018-04-26

在C57BL/KaLwRij小鼠皮下接种表达绿色荧光蛋白的5TGM1肿瘤的临床前免疫健全髓外多发性骨髓瘤模型中,评估18F-FDOPA(靶向L型氨基酸转运体1,LAT1,亦介导美法仑摄取)与18F-FDG PET/CT显像美法仑治疗反应。美法仑治疗使两种示踪剂的病灶亲和力和摄取均出现统计学显著降低;18F-FDOPA PET/CT对18F-FDG PET/CT显像美法仑治疗反应形成补充,18F-FDOPA摄取与LAT1表达及美法仑反应相关。

要点

  • 美法仑治疗使18F-FDG和18F-FDOPA的病灶亲和力与摄取均出现统计学显著降低。
  • 第2周治疗组LAT1密度增加,GLUT1表达未见可见变化。
  • 18F-FDOPA PET/CT对18F-FDG PET/CT显像临床前髓外多发性骨髓瘤美法仑治疗反应形成补充。

核心结论

  • 18F-FDOPA PET/CT对18F-FDG PET/CT显像临床前髓外多发性骨髓瘤美法仑治疗反应形成补充。
  • 18F-FDOPA摄取与LAT1表达及美法仑反应相关,纵向显像提示LAT1水平稳定和美法仑肿瘤细胞毒性。

研究设计与样本

  • C57BL/KaLwRij小鼠皮下接种单侧表达绿色荧光蛋白的小鼠5TGM1肿瘤,分为3个独立组:未治疗组、肿瘤植入后第2周开始治疗组、肿瘤植入后第3周开始治疗组。
  • 未治疗组和第2周治疗组于第4周在相邻的不同日期接受临床前MRI及动态18F-FDG和18F-FDOPA PET/CT显像;第3周治疗组每周纵向显像共3周。
  • 对两种示踪剂计算代谢性肿瘤体积、总病灶亲和力、SUVmax和总摄取;对所有组的代表性组织进行LAT1和葡萄糖转运体1(GLUT1)表达的免疫组织化学检测。

主要发现

  • 美法仑治疗使18F-FDG和18F-FDOPA的病灶亲和力和摄取均出现统计学显著降低。
  • GLUT1表达未见可见变化,但第2周治疗组LAT1密度增加。
  • 第3周治疗组纵向显像显示18F-FDG和18F-FDOPA摄取变化不一,其中18F-FDOPA病灶亲和力在第二周较基线升高。
  • 未治疗组和第3周治疗组的LAT1和GLUT1表面密度定性相似。

关键数值与推荐

  • 计算指标包括代谢性肿瘤体积、总病灶亲和力、SUVmax和总摄取,均针对18F-FDG和18F-FDOPA两种示踪剂。
  • 免疫组织化学检测LAT1和GLUT1表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来工作将探索其他具有异质性LAT1表达和对美法仑治疗反应的骨髓瘤细胞系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necessitating the stratification of responding patients to minimize toxicities and improve quality of life. Here, we evaluated the use of 3,4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA), a clinically available PET radiotracer with specificity to the L-type amino acid transporter 1 (LAT1), which also mediates melphalan uptake, for imaging melphalan therapy response in a preclinical immunocompetent model of MM. Methods: C57BL/KaLwRij mice were implanted subcutaneously with unilateral murine green fluorescent protein-expressing 5TGM1 tumors and divided into 3 independent groups: untreated, treated beginning week 2 after tumor implantation, and treated beginning week 3 after tumor implantation. The untreated and week 2 treated groups were imaged with preclinical MRI and dynamic 18F-FDG and 18F-FDOPA PET/CT at week 4 on separate, contiguous days, whereas the week 3 treated group was longitudinally imaged weekly for 3 wk. Metabolic tumor volume, total lesion avidity, SUVmax, and total uptake were calculated for both tracers. Immunohistochemistry was performed on representative tissue from all groups for LAT1 and glucose transporter 1 (GLUT1) expression. Results: Melphalan therapy induced a statistically significant reduction in lesion avidity and uptake for both 18F-FDG and 18F-FDOPA. There was no visible effect on GLUT1 expression, but LAT1 density increased in the week 2 treated group. Longitudinal imaging of the week 3 treated group showed variable changes in 18F-FDG and 18F-FDOPA uptake, with an increase in 18F-FDOPA lesion avidity in the second week relative to baseline. LAT1 and GLUT1 surface density in the untreated and week 3 treated groups were qualitatively similar. Conclusion:18F-FDOPA PET/CT complemented 18F-FDG PET/CT in imaging melphalan therapy response in preclinical extramedullary MM. 18F-FDOPA uptake was linked to LAT1 expression and melphalan response, with longitudinal imaging suggesting stabilization of LAT1 levels and melphalan tumor cytotoxicity. Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hathi DK, DeLassus EN, Achilefu S, et al. Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with 18F-FDOPA and 18F-FDG PET. J Nucl Med. 2018. PMID: 29700126. doi:10.2967/jnumed.118.208744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。